

3

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 51278

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Real life efficacy and safety of direct-acting antiviral therapy for treatment of hepatitis C-infected patients with genotypes 1, 2 and 3 in northwest China

Yang Y *et al.* DAAs for the treatment of genotype 1, 2 and 3 HCVs

Abstract

BACKGROUND

Regimens involving direct-acting antiviral agents (DAAs) are recommended

Match Overview

1	Crossref 14 words Aaron P. Thrift, Hashem B. El-Serag, Fasiha Kanwal. "Global epidemiology and burden of HCV infection and HCV-related..."	<1%
2	Internet 14 words crawled on 30-Nov-2018 www.nejm.org	<1%
3	Internet 14 words crawled on 19-Oct-2019 f6publishing.blob.core.windows.net	<1%
4	Crossref 13 words Fabris, P. "Alcohol is an important co-factor for both steati... is and fibrosis in Northern Italian patients with chronic hepatit	<1%
5	Crossref 13 words "Abstracts of the 27th Annual Conference of APASL, Marci... 14-18, 2018, New Delhi, India", <i>Hepatology International</i> , 20	<1%
6	Crossref 13 words Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Nara ng et al. "Impact of Direct Acting Antiviral Therapy for Treatm	<1%
7	Crossref 12 words "Clinical Dilemmas in Viral Liver Disease", Wiley, 2010	<1%



Real life efficacy and safety of direct-acting antiviral therapy for



ALL

IMAGES

VIDEOS

开启取词

3,260 Results

Any time ▾

'Real-life' experience with direct-acting antiviral agents ...

<https://journals.sagepub.com/doi/full/10.1177/0391398818763478>

We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a 'real-world' group of patients with end-stage renal disease.

Author: Rebeca García-Agudo, Sami Aoufi-Ra... Publish Year: 2018

Real-World Efficacy and Safety of Pangenotypic Direct ...

www.eurekaselect.com/170497/article

Notably, real-world studies have confirmed the efficacy and safety of pangenotypic DAA combinations reported in registration trials. The aim of this study was to review the treatment recommendations, and the efficacy and safety data of anti-HCV pangenotypic drugs reported in registration clinical trials and in recent real-life cohort studies.

Cited by: 3 Author: Riccardo Scotto, Antonio Riccardo Buono...

Publish Year: 2019

Status of Direct-Acting Antiviral Therapy for Hepatitis C ...

[https://www.gastrojournal.org/article/S0016-5085\(18\)35155-2/fulltext](https://www.gastrojournal.org/article/S0016-5085(18)35155-2/fulltext)

Whereas the 8-week regimen of sofosbuvir and ledipasvir has been approved by the FDA for select treatment-naïve patients without cirrhosis with HCV genotype 1 infection, the 8-week glecaprevir and pibrentasvir regimen has been approved for all treatment-naïve patients and those previously treated with interferon and ribavirin, without cirrhosis, infected with HCV genotypes 1, 2, 4, 5, or 6, and all ...

Cited by: 7 Author: Thomas F. Baumert, Thomas F. Baumert,...

Publish Year: 2019

[PDF] Treatment of hepatitis C: Results in real life

<https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.13638>

in genotypes 1, 2 and 3, respectively. • Real-world data highlight the ongoing challenges of defining optimal regimens for different subgroups and managing patients with cirrhosis. • In real life, most patients will be taking multiple medications to manage comorbidities and potential drug-drug interactions must be managed appropriately.

Cited by: 20 Author: Christophe Hézode


Publish Year: 2018

Impact of Direct Acting Antiviral Therapy for Treatment of ...


Hepatitis C

Medical Condition

Bloodborne disease characterized by fatigue, feeling sick, yellowing of skin and eyes



A viral infection that causes inflammation of liver.

-  Common (More than 200,000 cases per year in US)
-  Transmitted through blood contact
-  Often requires lab test or imaging
-  Treatment from medical professional advised
-  Can last several months or years

A blood borne virus and commonly transmitted through blood. Most of the people show no symptoms or experience a mild illness which may include fatigue, abdominal pain, loss of appetite, nausea or yellow discoloration of eyes and skin. Although no vaccine for hepatitis C is available. Medicines can cure most cases of hepatitis C.

Symptoms

During the acute phase (first 6 months after infection) most persons show no symptoms or might experience a mild illness.

During the chronic phase the symptoms include:

Chat with Bing



Oh! Let me guess why you search for this.

Say something...



国内版

国际版

Real life efficacy and safety of direct-acting antiviral therapy f



All

Images

Videos

关闭取词

2,530 Results

Any time ▾

Impact of Direct Acting Antiviral Therapy for Treatment of ...

<https://www.sciencedirect.com/science/article/pii/S0973688317304048>

Impact of Direct Acting **Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life** Experience from India. ... A.M. Aghemo, G. Cologni, F. Maggiolo, et al. **Safety** and **efficacy** of directly acting antivirals in 2432 HCV **patients** with advanced fibrosis: an interim analysis of the Lombardia Regional Network for Viral **Hepatitis**.

Cited by: 2

Author: Varun Mehta, Ramit Mahajan, Vandana Mid...

Publish Year: 2017

Real-World Efficacy and Safety of Pangenotypic Direct ...

www.eurekaselect.com/170497/article ▾

Background: Advances in the development of Direct-Acting Antivirals (DAAs), particularly pangenotypic drugs, have led to a high rate of **hepatitis C virus (HCV)** eradication. Notably, **real-** world studies have confirmed the **efficacy and safety** of pangenotypic DAA combinations reported in registration trials.

Cited by: 3

Author: Riccardo Scotto, Antonio Riccardo Buonom...

Publish Year: 2019

'Real-life' experience with direct-acting antiviral agents ...

<https://journals.sagepub.com/doi/full/10.1177/0391398818763478>

All-oral, interferon-free **therapy** with direct-acting **antiviral** agents for chronic **hepatitis C virus** in advanced chronic kidney disease was effective and well tolerated in a '**real-life**' clinical setting. Careful monitoring of haemoglobin and serum creatinine during **therapy** with direct-acting **antiviral** agents is suggested.

Author: Rebeca García-Agudo, Sami Aoufi-Rabi...

Publish Year: 2018

Status of Direct-Acting Antiviral Therapy for Hepatitis C ...

[https://www.gastrojournal.org/article/S0016-5085\(18\)35155-2/fulltext](https://www.gastrojournal.org/article/S0016-5085(18)35155-2/fulltext)

Rapid advances in **therapy** with oral direct-acting antivirals (DAAs) have resulted in significant improvement in **safety** and **efficacy**—7 all-oral regimens have been approved by the US Food and Drug Administration (FDA) for **treatment** of chronic **hepatitis C virus (HCV)** infection.

Cited by: 7

Author: Thomas F. Baumert, Thomas F. Baumert, T...

Publish Year: 2019

Safety and efficacy of direct acting antivirals for the ...

https://www.researchgate.net/publication/311679521_Safety_and_efficacy_of_direct...

... Interferon-free regimens are safe and highly effective, allowing **treatment** for elderly chronic HCV-infected **patients** without any age limit. [6][7][8][9] However ...